- Analysts are out with a bevy of upbeat coverage initiations for Five Prime Therapeutics (FPRX).
- Jefferies: Buy, PT $20.
- Wells Fargo: Outperform, PT $18.
- Guggenheim: Buy, PT $20.
- BMO: Outperform, PT $24.
- Look for data from a Phase 1b trial of GSK-partnered FP-1039 (it's an FGF pathway inhibitor) late next year.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs